A Randomized, Single-Dose, Open-Label, Parallel-Group Study in Healthy Volunteers to Assess the Relative Bioavailability of a Subcutaneous Dose of Nemolizumab When Administered With Auto-Injector Compared to Dual-Chamber Syringe
Latest Information Update: 06 Jan 2025
At a glance
- Drugs Nemolizumab (Primary)
- Indications Atopic dermatitis; Prurigo nodularis; Pruritus; Scleroderma
- Focus Pharmacokinetics
- Sponsors Galderma Research & Development
Most Recent Events
- 13 Dec 2022 Status changed from active, no longer recruiting to completed.
- 10 Oct 2022 Planned End Date changed from 31 Jan 2023 to 13 Dec 2022.
- 10 Oct 2022 Planned primary completion date changed from 31 Dec 2022 to 11 Nov 2022.